<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010343</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-PCa2020-01</org_study_id>
    <nct_id>NCT05010343</nct_id>
  </id_info>
  <brief_title>Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer</brief_title>
  <official_title>Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer: a Phase II Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II randomized controlled clinical trial to assess the toxicities and clinical&#xD;
      efficacy of prostate specific membrane antigen (PSMA) positron emission tomography / computed&#xD;
      tomography (PET/CT) and multi- parameter Magnetic Resonance Imaging (MRI) guided simultaneous&#xD;
      integrated boost for prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local recurrences of prostate cancer following radiotherapy often originate from the primary&#xD;
      tumor site. Therefore,focal boost to the primary gross tumor has been proposed to increase&#xD;
      biochemical disease-free survival (bDFS) without increasing toxicity.&#xD;
&#xD;
      The higher relative biological effectiveness (RBE) and greater cytocidal effect on the&#xD;
      intrinsic radiation resistant cancer cells offer carbon ion radiotherapy (CIRT) advantages&#xD;
      over conventional radiotherapy. In this study, carbon ion were used to treat localized&#xD;
      prostate cancer and simultaneous integrated boost to the gross tumor in the prostate specific&#xD;
      membrane antigen (PSMA) PET/CT and multi- parameter MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicities</measure>
    <time_frame>Within 3 months of the start of CIRT</time_frame>
    <description>Treatment related acute toxicity assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicities</measure>
    <time_frame>3 months after the completion of CIRT</time_frame>
    <description>Treatment related late toxicity assessed by Radiation Therapy Oncology Group (RTOG) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical failure free survival</measure>
    <time_frame>From the complation of CIRT,a median of 5 years</time_frame>
    <description>The prostate specific antigen less than nadir plus 2ng/ml (Phoenix definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the diagnosis of prostate cancer,a median of 5 years</time_frame>
    <description>The time from diagnosis to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From the complation of CIRT,a median of 5 years</time_frame>
    <description>The time from complation of CIRT to tumor progression or death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The quality of life-International Prostate Symptom Score (IPSS)</measure>
    <time_frame>From the complation of CIRT, a median of 5 years</time_frame>
    <description>IPSS would be used to assess the severity of lower urinary tract symptoms, based on the answers to seven questions regarding urinary symptoms (incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia).&#xD;
Total IPSS score: 1-7: Mild; 8-19: Moderate; 20-35: Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>The quality of life-Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>From the complation of CIRT, a median of 5 years</time_frame>
    <description>EPIC would be used to evaluate the urinary, bowel, and sexual symptoms. The EPIC is a patient reported outcomes instrument designed to evaluate bowel, urinary, sexual and hormonal domains both during and after irradiation of the pelvis.For each domain, responses are provided on a 5-point Likert scale, and multi-item scale scores are transformed linearly to a scale of 0 to 100, where higher scores correspond to better quality of life.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Localized Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>carbon ion irradation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbon Ion Irradiation With SIB group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>carbon ion irradation</intervention_name>
    <description>All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle</description>
    <arm_group_label>carbon ion irradation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon Ion Irradiation With SIB</intervention_name>
    <description>All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI</description>
    <arm_group_label>Carbon Ion Irradiation With SIB group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed adenocarcinoma of prostate&#xD;
&#xD;
          -  Stage cT1-3N0M0 localized prostate cancer&#xD;
&#xD;
          -  performed PSMA PET/CT and mpMRI before treatment&#xD;
&#xD;
          -  No lymph nodes or distant metastasis&#xD;
&#xD;
          -  Age ≥ 45 and &lt; 85 years of age&#xD;
&#xD;
          -  Karnofsky Performance Score ≥70&#xD;
&#xD;
          -  No previous pelvic radiation therapy (RT)&#xD;
&#xD;
          -  No previous prostatectomy&#xD;
&#xD;
          -  No previous invasive cancer (within 5 years before the prostate cancer diagnosis)&#xD;
&#xD;
          -  Ability to understand character and individual consequences of the clinical trial&#xD;
&#xD;
          -  Willing to sign the written informed consent; Informed consent must be signed before&#xD;
             the enrollment in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No pathologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Pelvic lymph node metastasis (N1)&#xD;
&#xD;
          -  Distant metastasis (M1)&#xD;
&#xD;
          -  Previous pelvic radiotherapy&#xD;
&#xD;
          -  Previous prostatectomy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li</last_name>
      <phone>38296666</phone>
      <email>ping.li@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qing Zhang</last_name>
      <phone>38296666</phone>
      <email>qing.zhang@sphic.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Ping Li</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>carbon ion irradiation</keyword>
  <keyword>Simultaneous Integrated Boost</keyword>
  <keyword>PSMA PET/CT</keyword>
  <keyword>mpMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

